Upload
myles-hines
View
214
Download
0
Tags:
Embed Size (px)
Citation preview
Rafael Laniado-Laborin MD, MPH, FCCP
Universidad Autónoma de Baja California
Tuberculosis and HIV/AIDS
Background
The World Health Organization (WHO)
estimates that approximately one third of the
total population of the world harbors tubercle
bacilli in a latent form A new infection occurs every secondA new infection occurs every second
Int J Tuberc Lung Dis 2003; 7:S328
Background
IUTLD-NAR Meeting 2006
The WHO also estimates that each year
more than 9 million new cases of tuberculosis
occur and approximately 2 million persons
die from the disease One case can infect from 10 to 15 One case can infect from 10 to 15
peoplepeople
How frequent is the co-infection?
TB cases in persons with HIV co-infection, USA 1993-2003 (25-44 years old)
29 2926 25
21 20 1917 16 16 16
0
5
10
15
20
25
30
35
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
(%)
CDC Website, Sep 2006CDC Website, Sep 2006
CACA
AZAZ NMNM
TXTXSONSON
CHI COHCOH
TAM
NLNL
BC25.325.3
18.711.711.7
31.1
41.5
21.9
8.38.3
4.74.7 2.22.2
7.57.5
SOURCE: DGE MEXICO / CDC EUA
TB: Border states USA & Mexico
Bacteriology
MTB belongs to the
genus Mycobaterium
Mycobacterium
tuberculosis complex
o M. tuberculosis
o M. bovis
o M. africanum
o M. microti
o M. canetti
Nontuberculous mycobacterium (MOTT) In the US up 30 % of the isolates are NTM
(rate: 1.8 per 100,000 h. The most common NTM are:
o Mycobacterium avium complex (60 %)
o Mycobacterium fortuitum (20 %)
o Mycobacterium kansasii (10 %)
Pathogenesis Tuberculosis is spread from person to person
through the air by droplet nuclei, particles <5 mm in diameter that contain M. tuberculosis complex
Pathogenesis
4 factors determine the risk of infection: o the number of organisms
being expelled into the airo the concentration of
organisms in the air (volume of the space and its ventilation)
o the length of time an exposed person breathes the contaminated air
o the immune status of the
exposed individual
HIV-infected persons and others with impaired cell-mediated immunity are thought to be more likely to become infected with M. tuberculosis after exposure than persons with normal immunity
Also, HIV-infected persons and others with impaired cell-mediated immunity are much more likely to develop disease if they are infected
Pathogenesis
Inhalation and deposition in the lungs of the tubercle bacillus leads to one of four possible outcomes:o immediate clearance of the organism
o chronic or latent infection
o rapidly progressive disease (or primary disease)
o active disease months to years after the infection (reactivation disease)
Pathogenesis
Only 5 to 10 percent of patients with no underlying medical problems who become infected develop active disease in their lifetime
The risk increases markedly in patients with AIDS
Pathogenesis
Once they are inhaled, the bacilli will
reach the distal bronchioles and alveoli
Inside the alveolar macrophages M.
tuberculosis will multiply slowly (once
every 24-32 hours) and kill the cell
Pathogenesis
The infected macrophages produce cytokines that attract other phagocytic cells which eventually form a nodular granulomatous structure called the tubercle
Pathogenesis
If the bacterial replication is not controlled, the tubercle enlarges and the bacilli enter the local draining lymph nodes
The lesion produced by the expansion of the tubercle into the lung parenchyma and lymph node involvement is called the Ghon complex
Primary complex (Gohn’s)
Pathogenesis
Failure by the host to mount an effective CMI response and tissue repair leads to progressive destruction of the lung
If the bacterial growth continues to remain
unchecked, the bacilli may spread
hematogenously to produce disseminated TB
HIV-infected persons, especially those with low CD4+ cell counts, develop tuberculosis disease rapidly after becoming infected with M. tuberculosis
Up to 50 percent of such persons may do so in the first two years after infection with M. tuberculosis
Conversely, an individual who has a prior
latent infection with M. tuberculosis (not
treated) and then acquires HIV infection will
develop tuberculosis disease at an
approximate rate of 5 to 10 percent per year
Voluntary HIV counseling and testing is recommended for all patients with TB and should be considered the standard of care
Am J Respir Crit Care Med 2005; 172:1169Am J Respir Crit Care Med 2005; 172:1169
Physicians who provide primary care to persons with HIV infection or populations at increased risk for HIV infection should maintain a high index of suspicion for TB
Every patient in whom HIV infection has been newly diagnosed should be assessed for the presence of TB or LTBI
Am J Respir Crit Care Med 2005; 172:1169Am J Respir Crit Care Med 2005; 172:1169
The risk depends, however, on the degree of
immunosuppression—the risk of a patient
with AIDS developing tuberculosis is 170
times higher than a non immunosuppressed
person
Reactivation disease
Reactivation TB results when the persistent bacteria in a host suddenly proliferate
While immunosuppression is clearly associated with reactivation TB, it is not clear what host factors specifically maintain the infection in a latent state for many years and what triggers the latent infection to become overt
Reactivation disease
Immunosuppressive conditions associated with reactivation TB include:o HIV infection and AIDSHIV infection and AIDS
o end-stage renal disease
o diabetes mellitus
o malignant lymphoma
o corticosteroid use
o old age
Clinical manifestations
Clinical manifestations
In immunocompetent individuals, 85% of the cases are exclusively pulmonary, and the rest have extrapulmonary manifestations
This distribution is modified in HIV patients: o 38% exclusively pulmonary
o 30% extrapulmonary
o 32% pulmonary + extrapulmonary
Systemic manifestations
Fever (37-80%)
Weight loss
Night sweats
Loss of appetite
Malaise
Pulmonary TB
Cough: is the most common symptom
Sputum, hemoptysis
Pleuritic pain
Dyspnea
Radiographic manifestations
Radiographic findings
PTB is almost associated to radiographic
abnormalities
Patients with HIV and PTB might have a
normal chest x-ray
Radiographic findings
In patients with HIV infection, the nature of the x-ray findings depends to a certain extent on the degree of immunocompromise produced by the HIV infection
TB that occurs relatively early in the course of HIV infection tends to have the typical x-ray findings of the immunocompetent patient
Radiographic findings
With more advanced HIV disease the
radiographic findings become more
"atypical": cavitations is uncommon, and
lower lung zone or diffuse infiltrates and
intrathoracic adenopathy are frequent
Disseminated tuberculosis
Disseminated tuberculosis
The term "miliary" is derived from the visual similarity of some disseminated lesions to millet seeds
Grossly, these lesions are 1- to 2-mm yellowish nodules that, histologically, are granulomas
Thus disseminated tuberculosis is sometimes called "miliary" tuberculosis
Disseminated TB
Because of the multisystem involvement in disseminated tuberculosis, the clinical manifestations are protean
The presenting symptoms and signs are generally nonspecific and are dominated by systemic effects, particularly fever, weight loss, night sweats, anorexia, and weakness
Other symptoms depend on the relative severity of disease in the organs involved
Disseminated TB
Laboratory diagnosis
Diagnosis
Microscopy:o this is principally applied to sputum but other
specimens include bronchoalveolar lavage fluid, gastric washings, laryngeal swabs, cerebrospinal fluid, pleural, pericardial and peritoneal effusions, fine needle lymph node aspirates, bone marrow aspirates, and tissue biopsies.
Diagnosis
A wide range of acid-fast smear positivity has been reported (31 to 81 percent), but most studies find a 50 to 60 percent yield
The yield is substantially higher (85 to 100 percent) on sputum culture
Mycobacteria cultures
Diagnosis
In patients infected with HIV, a positive smear for acid-fast bacilli (AFB) is very specific for Mycobacterium tuberculosis (MTB), even in a setting with a high incidence of Mycobacterium avium complex (MAC)
Diagnosis
At San Francisco General Hospital, for example, 248 of 271 (92 percent) expectorated sputum samples which were positive for AFB grew MTB on culture
This value is comparable to that found in HIV-negative patients.
Diagnosis
Urine cultures – Although genitourinary TB rarely occurs in the absence of other sites of extrapulmonary disease, it is frequently involved in disseminated TB, even in the absence of pyuria
In one series, for example, 77% HIV-infected patients with extrapulmonary TB whose urine was sent for culture grew MTB
Diagnosis
Invasive testing should be performed when noninvasive studies yield no immediate answer and the wait for culture results would be detrimental to the patient
Bronchoscopy is a sensitive technique for diagnosing TB
An immediate diagnosis can be made from AFB smears in about one-half of patients, and the sensitivity of cultures approaches 100 percent
Diagnosis
The central nervous system is frequently involved in disseminated TB
Given the number of opportunistic infections affecting the central nervous system in AIDS, there should be a low threshold for collecting CSF
Diagnosis
In a patient with suspected miliary disease and a negative sputum examination, bone marrow biopsy as well as blood cultures should be performed
Blood cultures are positive in 49 percent of patients with disseminated disease and CD4 counts less than 100/mm3
Molecular methods
The application of nucleic acid (DNA and RNA) amplification techniques—the polymerase chain reaction (PCR) and the ligase chain reaction (LCR)—is the subject of intense research activity
As a result, a number of rapid, sensitive, and specific test kits are commercially available
Diagnosis of LTBI
TST is considered as positive if > 5 mm
Contacts of an active TB case
Subjects with a chest x-ray anomalies
(fibrosis) suggestive of old (untreated) TB
Immunosuppression (including HIV)Immunosuppression (including HIV)
Drug induced immunosuppression ( >15
mg/day of prednisone)
Patients with 5 mm or more of induration be considered to have a positive test and should receive, in addition to chest x-rays, a clinical evaluation to rule out TB
Am J Respir Crit Care Med 2005; 172:1169Am J Respir Crit Care Med 2005; 172:1169
IFN- assays
Patient’s T cells release IFN- when exposed to mycobacterial antigens
The genes encoding for two antigenic targets, ESAT6 and CFP10 are absent in the BCG vaccine strain and most environmental mycobacteria
Eur Respir J 2006; 28:1-3Eur Respir J 2006; 28:1-3
IFN- assays
There are two different assay formats:o ELISA detection after blood is incubated in a tube
with ESAT6/CPF10 antigens (Quantiferon-Gold)
o ELISA immunospot technique (T-Spot.TB) Advantage: one blood sample; no repeated
visits as in TST Disadvantage: cost
Eur Respir J 2006; 28:1-3Eur Respir J 2006; 28:1-3
IFN- assays
These assays are not as sensitive for diagnosing active TB since IFN- responses decline as TB develops
Eur Respir J 2006; 28:1-3Eur Respir J 2006; 28:1-3
75 individuals with active TB and control group (HS students
with risk of infection)Active TB Immuno
Controls
(specificity)
TST 72% 37% 82%
T-Spot.TB 96% 100% 86%
QF-Gold 77% 75% 92%
Eur Respir J 2006; 28:24-30Eur Respir J 2006; 28:24-30
Guidelines for using the QF-Gold test
CDC 2005/54(RR15):49-55 FDA approved Diagnosing infection with M. tuberculosis
including both TB disease and LTBI QF-G can be used in all circumstances in
which the TST is used
Guidelines for using the QF-Gold test
CDC 2005/54(RR15):49-55 QF-G can be used in place of (and not in addition to) TST
A positive QF-G result should prompt the same public health and medical interventions as a positive TST result
Treatment
Treatment of HIV related tuberculosis The standard WHO recommended
antituberculosis regimen is a six month course of RIF and INH, PZA, together with ETH (or SM) during the first two months of treatment
Supplementation with daily pyridoxine (vitamin B6) to prevent isoniazid induced neuropathy is now routine
There is little or no difference in relapse rate between HIV infected and uninfected patients when RIF based short course treatment is used
Thus, in the absence of drug resistance, the standard short course just described is recommended
Antituberculous drug interactions A number of interactions between
antituberculosis agents and other drugs have been described
Most interactions are associated with RIF due to its ability to induce cytochrome CYP450 enzymes in the liver which affect the metabolism of many other drugs
Antituberculous drug interactions The current recommendation is to replace
RIF by rifabutin, a much less powerful inducer of cytochrome enzymes, and to start or continue with the antiretroviral drugs
Management recommendations for the use
of ARV + antituberculosis drugs
Frequent communication between TB and HIV care providers
Adjust dose of rifabutin as needed Use rifampin with efavirenz or ritonavir (>400
mg BID)
Am J Respir Crit Care Med 2001; 164:7-12Am J Respir Crit Care Med 2001; 164:7-12
Antituberculous drug interactions Even if rifabutin is substituted for RIF, care
should be exercised in the use of the protease inhibitor saquinavir and the non-nucleoside reverse transcriptase inhibitors as rifabutin decreases their levels, with the risk of selection of drug resistant viruses
It appears usually after two weeks of ARV
treatment
Most of the patients have far advance AIDS
o median CD4+: 35 cells/mm3
o median viral load: 581,694 copies/mL
Immune reconstitution syndrome
Paradoxical reactions (immune reconstitution syndrome) These manifest as fever, enlargement of
affected lymph nodes, and a worsening of the radiological appearance
Paradoxical reactions (immune reconstitution syndrome) These reactions are not indicative of
treatment failure and usually subside spontaneously
Treatment should not be modified but short courses of steroids may be required for severe paradoxical reactions.
When should ART be started? ARVs should be given to those with WHO
Stage IV disease, including individuals with extra-pulmonary TB, regardless of CD4 T-cell count
Int J Tuberc Lung Dis 2005; 9:946Int J Tuberc Lung Dis 2005; 9:946
Those with Stage III conditions, including individuals with pulmonary TB (PTB), should have CD4 T-cell counts taken into consideration; treatment is recommended when counts are <350 cells/mm3
Those with Stage I and II disease should only receive ART for CD41 T-cell counts <200 cells/mm3
When should ART be started?
Int J Tuberc Lung Dis 2005; 9:946Int J Tuberc Lung Dis 2005; 9:946
Treatment of LTBI
Incidence of active TB in PPD positive subjects according to risk
factorRisk factor
TB cases /1000 patient-years
TB infection<1 year 12.9
TB infection 1-7 years 1.6
HIV infection 35-162
IV drug use (HIV negative) 10
x-ray abnormality (old TB) 2-13.6
Weight loss >15% 2.6
Weight loss 10-14% 2.0
It has been used for more than 30 years Evidence is classified as:
o A= preferred treatment
o B= acceptable alternative
o C= offer if A and B are not an option
o I= randomized clinical trial
o II= clinical trail; not randomized
o III= experts opinion
Treatment of LTBI
Targeted testing and treatment for LTBI are strongly recommended at the time the diagnosis of HIV infection is established (AII)
Am J Respir Crit Care Med 2005; 172:1169Am J Respir Crit Care Med 2005; 172:1169
Persons with known or suspected HIV infection who have contact with a patient with infectious pulmonary TB should be offered a full course of treatment for LTBI regardless of the initial result of tuberculin skin testing once active TB has been ruled out (AII)
Am J Respir Crit Care Med 2005; 172:1169Am J Respir Crit Care Med 2005; 172:1169
In view of the very high risk of a co-infected person developing active TB, and the adverse effect of this disease on the immune status and survival of the patient, there is a very good theoretical case for provision of prophylactic treatment for those at risk
Prophylaxis against TB in co-infected persons
Treatment of LTBI
In the initial studies, a 12 month course of isoniazid was found to lower the incidence of tuberculosis in co-infected persons
Subsequently, shorter combination regimens have also been shown to be effective
DrugsDuration (months)
Interval HIV- HIV+
INH 9Daily
Bi-weekly
A(II)
B(II)
A(II)
B(II)
INH 6Daily
Bi-weekly
B(I)
B(II)
C(I)
C(I)
RIF-PZA2
2-3
Daily
Bi-weekly
B(II)
C(II)
A(I)
C(I)
RIF 4 Daily B(II) B(II)
An HIV-infected patient who is severely immunocompromised and whose initial tuberculin skin test result is negative should be retested after the initiation of antiretroviral therapy and immune reconstitution, when CD4 cell counts are greater than 200 cells/l (AII)
Am J Respir Crit Care Med 2005; 172:1169Am J Respir Crit Care Med 2005; 172:1169
BCG VACCINATIO
N
BCG VACCINATIO
N
Results of randomized controlled trials (RCT)
and case control studies (CCS) showed the
protective efficacy against tuberculosis as
uncertain and unpredictable, as protective
efficacy varied from 0 to 80%
Is BCG effective?
BCG: a meta-analysis
Meta-analysis of over 1,200 articles from
international publications
Only 14 prospective trials and 12 case-
control studies met the selection criteria
JAMA 1994; 271:698-702JAMA 1994; 271:698-702
BCG: a meta-analysis
Combining data from the trials the RR for TB
among those vaccinated with BCG was 0.49
(95%CI, 0.34 to 0.70); protective effect 51%
Combining data from the case-control
studies, the OR for BCG vaccination
against TB was 0.50 (95%CI 0.39 to 0.64)
JAMA 1994; 271:698-702JAMA 1994; 271:698-702
Immunization of children at risk of infection with HIV
The available data is not adequate to permit
definitive conclusions about the effectiveness
of BCG vaccine to protect HIV-infected
children or adults against tuberculosis
Bull World Health Org 2003;81:61Bull World Health Org 2003;81:61
BCG vaccination
There is a risk that vaccination with Bacille Calmette-Guérin (BCG), a living attenuated vaccine, will cause infectious complications in HIV positive persons
There is a small increase in the incidence of adverse effects of BCG in the children of HIV infected women, but most such effects are mild
A consensus view currently exists, however,
that BCG should not be given to infants with
active HIV disease and that the vaccine is
contraindicated in older asymptomatic
children who are found to be HIV positive
Adverse events associated with BCG vaccination in children
infected with HIV
Dissemination 0-31%
Lymphadenitis 0-24%
Bull World Health Org 2003;81:61Bull World Health Org 2003;81:61
More than 28 cases of disseminated BCG
infection have been reported in HIV-infected
children and adults
Progressive immune suppression can lead
to the reactivation of latent BCG organisms,
causing regional or disseminated disease
Adverse events associated with BCG vaccination in children
infected with HIV
Bull World Health Org 2003;81:61Bull World Health Org 2003;81:61